Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients

Inclusion Criteria

• Patients >= 18 years of age with a diagnosis of breast cancer
• Patients receiving 12-18 weeks of chemotherapy with a taxane-based regimen (4 cycles of weekly x 3 paclitaxel or 4-6 cycles of docetaxel every 3 weeks)
• Absence of sensory peripheral neuropathy, skin or nail disorders at the start of treatment
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
• Ability to complete questionnaires by themselves or with assistance
• Ability to give signed informed consent

Exclusion Criteria

• History of prior sensory/motor peripheral neuropathy from any cause
• History of prior Raynaud's phenomenon
• History of cryoglobulinemia
• Active peripheral vascular disease
• Cold intolerance
• Prior exposure to neurotoxic chemotherapy in the last 10 years
• Hand-foot syndrome
• Tumor metastasis in bone, soft tissue, or skin of the hands or feet
• Absence of one or more fingers or toes
• Prior exposure to taxane chemotherapy